April 7th, 2014
This week’s topics include SYMPLICITY HTN-3, CoreValve, MADIT-CRT, and more.
March 30th, 2014
Arthur J. Moss discusses his research group’s study of long-term survival for patients who received cardiac resynchronization therapy with a defibrillator in the MADIT-CRT trial.
September 17th, 2010
The FDA has expanded the indication for CRT-D devices made by Boston Scientific. Previously, the devices had been approved only in NYHA Class III and IV patients. The expanded indication now includes Class I and II patients who have left bundle branch block. The expanded indication is based on data from the MADIT-CRT trial. “This approval […]